AbCellera Biologics Inc vs Corsair Gaming Inc — how do they compare? AbCellera Biologics Inc trades at $9.97 (market cap $2.99B), while Corsair Gaming Inc trades at $12.94 (market cap $1.39B). The key difference: AbCellera Biologics Inc is far larger — about 2.2× Corsair Gaming Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | CRSR | |
|---|---|---|
Market Cap | $2.99B | $1.39B |
Sector | Health | Technology |
52-Week High | $9.76 | $14.35 |
52-Week Low | $2.78 | $4.58 |
Enterprise Value | $2.58B | $1.38B |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
Corsair Gaming (CRSR) trades at $12.96, down 5.47% today, but maintains a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with EPS of $0.23 versus $0.07 expected, and the company raised full-year guidance. Revenue for 2025 was $1.47 billion, though net income was negative $16.16 million, reflecting a net margin of -1.1%. The stock's valuation shows a P/E of 41.39 and P/S of 0.95, with analyst consensus leaning toward Hold but with a $12.40 price target slightly below current levels.
The outlook for CRSR is mixed; strong earnings beats and raised guidance signal operational improvement, but profitability remains a challenge with inconsistent net income. Key risks include competitive pressures in gaming hardware and reliance on consumer spending cycles. Upside potential hinges on sustained margin expansion and successful integration of recent acquisitions like Trak Racer.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →